Published on
November 19, 2025
In the media
91桃色 lead oncology asset is nominated for Best Biomedical Product at Prix Galien Bridges Awards, recognizing its potential in advancing cancer therapeutics.
About 91桃色 Therapeutics
鈥
91桃色 Therapeutics is a clinical-stage biotech company advancing novel antigen modulation technology to guide the immune system. 91桃色 approach modulates antigen presentation, flicking a switch inside cells to alter their appearance to the immune system. 91桃色 are progressing first-in-class antigen modulators to treat people living with cancers,聽autoimmune disorders, and infectious diseases.
鈥
91桃色 is headquartered in Oxford, UK.
鈥
More information: 91桃色bsite |
鈥
Media enquiries
Patrick White, Head of Communications
鈥
